| Document |
Document Title |
|
WO/2024/061097A1 |
Provided are an anti-platelet aggregation medicament and use thereof. The medicament is a compound having a structure of formula I, or a pharmaceutically acceptable salt thereof, a solvate thereof, or a deuterated substance thereof. The ...
|
|
WO/2024/062487A1 |
The invention provides folding oligonucleotides and uses thereof to rectify genetic mutations in a target RNA molecule, or to attach specific motifs to the target RNA molecule.
|
|
WO/2024/062445A1 |
A method for predicting disease incidence, progression, aggressiveness, and prognosis of brain tumors including gliomas and astrocytomas using palladin as a marker. Palladin expression is also disclosed as a therapeutic target for the tr...
|
|
WO/2024/062164A1 |
The invention relates to sagerinic acid and the compositions containing it, for use in the prevention and/or treatment of disorders related to senescence in humans and animals.
|
|
WO/2024/061253A1 |
The present invention relates to a crystal form of Emraclidine (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in the prepara...
|
|
WO/2024/061848A1 |
The present invention provides pharmaceutical compositions comprising polyinosinic- polycytidylic acid, in particular using particles formed by synthetic polymers, that are adapted for parenteral administration, such as for subcutaneous,...
|
|
WO/2024/064734A1 |
Provided herein are crystalline forms of 3-({[(4R)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro
-2H-1-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid, L-lysine salt, as histone demethylase inhibitors. Also provided herein a...
|
|
WO/2024/060911A1 |
Disclosed are a benzoisothiazole compound, and a pharmaceutical composition and use thereof. The present invention belongs to the technical field of medicines, and particularly relates to a novel structure 2H-benzotriazole-substituted be...
|
|
WO/2024/064210A1 |
Disclosed are compounds, compositions, and methods useful for boron neutron capture therapy.
|
|
WO/2024/062443A1 |
The present invention provides subcutaneous pharmaceutical injectable compositions comprising ketamine or its salt such as Ketamine Hydrochloride equivalent to Ketamine base 50mg/ml and stabilizer. The invention further provides a method...
|
|
WO/2024/063661A1 |
The subject matter of the invention is a pharmaceutical composition for topical application containing a beta- adrenergic receptor antagonist and a corticosteroid and use thereof in the treatment of hemangiomas in children.
|
|
WO/2024/064024A1 |
The present invention relates to ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives of formula (I) as well as to said compounds for use as P13K inhibitors in methods of treatment of cancer.
|
|
WO/2024/060834A1 |
The present invention relates to the technical field of biopharmaceuticals, and particularly, to use of fluoropyridoxal in preparing a medicament against a cancer, comprising: use in preparing a medicament for preventing and/or relieving...
|
|
WO/2024/063424A1 |
The present invention relates to microspheres comprising baricitinib, a method for producing same, and a pharmaceutical composition comprising same. The microspheres comprising baricitinib, according to the present invention, exhibit sta...
|
|
WO/2024/061300A1 |
Described herein are TREX1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with TREX1.
|
|
WO/2024/064854A2 |
Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of methyl CpG binding protein 2 (MECP2) RNA in a cell or animal, and in certain instances reducing the amo...
|
|
WO/2024/062389A1 |
The present disclosure provides polymorphs and formulations of l-(6- fluoro-5-(((( lr,3r)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl) amino)methyl)isoquinolin-8-yl)ethane-l,2-diol (compound I).
|
|
WO/2024/061346A1 |
Provided is use of a hypoxia-activated compound alone or in combination with a PARP inhibitor in the preparation of a medicament for treating a cancer patient. In particular, the patient is detected to have pathogenic gene mutations such...
|
|
WO/2024/059962A1 |
Provided is a pharmaceutical composition containing a therapeutically effective amount of furmonertinib or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, and use of furmonertinib or a pha...
|
|
WO/2024/059910A1 |
This disclosure relates to RNA interference (RNAi) reagents for treatment of SARS-CoV-2 infection, compositions comprising same, and use thereof to treat or prevent infection by SARS- CoV-2.
|
|
WO/2024/061608A1 |
The present invention relates to use of glycine or a composition comprising glycine in inhibiting the growth of Malassezia restricta when applied on an external surface of a human body; wherein the composition comprises at least 0.04% of...
|
|
WO/2024/061894A1 |
The present disclosure relates to the use of compounds such as compounds of Formula (I) or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, for example, in pharmaceutical compositions and in the treatment of diseases, ...
|
|
WO/2024/064026A1 |
Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
|
|
WO/2024/064366A2 |
Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
|
|
WO/2024/064757A1 |
The present disclosure provides liquid formulations comprising belumosudil, processes for preparing a liquid formulation of belumosudil, and liquid pharmaceutical compositions comprising belumosudil which may be used in the treatment of ...
|
|
WO/2024/064807A2 |
Methods of treatment of medulloblastoma by administering thyroid hormone (T3) to a subject are provided herein.
|
|
WO/2024/062363A1 |
The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as CBL-b inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and...
|
|
WO/2024/064536A1 |
The present invention includes a method of reducing or eliminating a cardiotoxic or cardiopathic effect of one or more active agents comprising: administering to a subject in need thereof an effective amount of one or more lipids that re...
|
|
WO/2024/064656A2 |
Provided herein are devices, systems, and methods of treating bone defects by wrapping thermoplastics around bone and molding thermoplastic to bone. Also provided herein are a sonotrode coupler and system used to perform the method. The ...
|
|
WO/2024/063611A2 |
The present invention relates to a hydroxy fatty acid and a hydroxy fatty acid derivative derived from long-chain fatty acids and functioning as agonists for fatty acid receptors such as GPR40 and GPR120. The hydroxy fatty acid and the h...
|
|
WO/2023/208109A9 |
The present invention relates to an siRNA capable of inhibiting HSD17B13 gene expression, an siRNA conjugate, a pharmaceutical composition comprising same, and a use thereof. Each nucleotide in the siRNA is independently a modified or un...
|
|
WO/2024/061185A1 |
One aspect of the present invention relates to an RNAi (dsRNA) duplex reagent capable of inhibiting the expression of a target gene. The dsRNA duplex has a F-modified nucleotide at a specific position in an antisense strand or sense stra...
|
|
WO/2024/062405A1 |
The present invention relates to thyroid hormones or their salts for the use in the treatment of autosomal dominant polycystic kidney disease.
|
|
WO/2024/062372A1 |
The present disclosure relates, inter alia, to combination therapies of an oncolytic adenovirus with a topoisomerase I inhibitor or prodrug thereof, such as topotecan or SN-38, or a prodrug of a topoisomerase inhibitor, such as irinoteca...
|
|
WO/2024/064027A1 |
Disclosed herein, in part, are liquid pharmaceutical formulations and unit liquid pharmaceutical formulations comprising a loop diuretic, and a pharmaceutically acceptable excipient. In certain embodiments, the formulations include a buf...
|
|
WO/2024/064729A1 |
Provided herein are methods to treat neurodegenerative disease.
|
|
WO/2024/064637A2 |
Compositions comprising an RNA molecule comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-11121 and methods and uses thereof.
|
|
WO/2024/063569A1 |
A pharmaceutical composition for disrupting tumor blood vessels, according to an exemplary embodiment, may comprise alkaline 5-fluorouracil and a nitric oxide production inhibitor. For example, if the present invention includes alkaline ...
|
|
WO/2024/063249A1 |
An electronic device according to one embodiment comprises: a cartridge accommodation unit for accommodating a cartridge in which an emulsion is contained; a crushing circuit including a crushing element capable of crushing at least a pa...
|
|
WO/2024/060912A1 |
The present invention provides a 2H-benzotriazole derivative, a preparation method therefor, and a pharmaceutical composition containing same, belongs to the technical field of medicines, and particularly relates to a 2H-benzotriazole de...
|
|
WO/2023/283434A9 |
The present disclosure relates generally to monomers and methods for conjugating one or more ligands to oligonucleotides.
|
|
WO/2024/064699A2 |
Dry cellulose-reinforced hydrogels may include a cellulose nanofiber network and an interstitial hydrogel portion within interstitial regions of the cellulose nanofiber network, the interstitial hydrogel portion comprising a hydrogel tha...
|
|
WO/2024/060520A1 |
The present invention relates to the field of pharmaceuticals, and particularly, to a medicament for preventing and treating a tumor and specifically, use of O6-methyl-2-deoxyguanosine-5-triphosphate (O6-methyl-dGTP) in preparing a medic...
|
|
WO/2024/062349A1 |
Hydroalcoholic single phase gel compositions comprising diclofenac or a pharmaceutically acceptable salt of diclofenac are disclosed. The compositions are single phase compositions, and don't contain a lipophilic phase. The compositions ...
|
|
WO/2024/061353A1 |
Disclosed are a crystal form of a quinazoline compound and a preparation method therefor. Particularly, disclosed are a crystal form of a compound of formula (I), a preparation method therefor, and use thereof.
|
|
WO/2024/061048A1 |
Disclosed are a class of lycorine derivatives represented by general formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition thereof, and use thereof. The lycorine derivatives ...
|
|
WO/2023/229685A9 |
The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of cytomegalovirus infection in humans. A new class of N-arylpyrimidamine (NAPA) small molecules is disclosed that ...
|
|
WO/2024/061658A1 |
The present invention provides compounds of general formula (I): or pharmaceuticaly acceptable salts, solvates or hydrates thereof, wherein RN is independently -H or - Me; RX is independently C1-4 alkyl, optionaly substituted with halo o...
|
|
WO/2024/064954A2 |
Compositions and methods are provided for the inhibition, treatment and/or prevention of Huntington's disease and related disorders.
|
|
WO/2024/064607A2 |
Compositions comprising an RNA molecule comprising a guide sequence portion having 17- 50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-37421 and methods and uses thereof.
|
